IP Library Granted Patent US 8,067,041
Granted Patent B2
US 8,067,041 · App. 12/476,590 · Granted Nov 29, 2011

Method for treatment of constipation-predominant irritable bowel syndrome

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,041
App. No.
12/476,590
Granted
Nov 29, 2011
Kind
B2
Abstract

The present invention provides methods for treating constipation-predominant irritable bowel syndrome comprising administering to a patient in need thereof, a polymeric proanthocyanidin composition from a Croton species or Calophyllum species in an amount sufficient to treat constipation-predominant irritable bowel syndrome (c-IBS). Treatment of c-IBS includes the treatment of the constipation component of c-IBS as well as the pain and abdominal discomfort associated with c-IBS. In one embodiment, the polymeric proanthocyanidin compound is crofelemer. The present invention in an alternative embodiment also provides methods for treating alternating constipation-predominant/diarrhea-predominant irritable bowel syndrome.

Claims (9)

1. A method of treating constipation-predominant irritable bowel syndrome (c-IBS), comprising administering to a patient in need of such treatment, an amount of an extract isolated from the latex of a Croton spp. or Calophyllum spp. effective to treat c-IBS, wherein said amount is bioequivalent to an orally administered dose of about 250 mg per day to about 4000 mg per day of crofelemer.

2. A method of treating constipation-predominant irritable bowel syndrome (c-IBS), comprising administering to a patient in need of such treatment, an amount of a polymeric proanthocyanidin composition isolated from the latex of a Croton spp. or Calophyllum spp. effective to treat c-IBS, wherein said amount is bioequivalent to an orally administered dose of about 250 mg per day to about 4000 mg per day of crofelemer.

3. The method of claim 2 , in which the polymer composition comprises at least one monomer selected from the group consisting of catechin, epicatechin, gallocatechin and epigallocatechin.

4. The method of claim 2 wherein the polymeric proanthocyanidin composition is crofelemer.

5. The method of claim 1 or 2 , in which the treatment comprises reducing one or more symptoms of c-IBS.

6. The method of claim 5 , in which the symptom is pain or abdominal discomfort.

7. The method of claim 6 , in which pain or discomfort is reduced by at least 10%.

8. The method of claim 5 , in which the symptom is constipation or less than normal stool frequency.

9. The method of claim 8 , in which stool frequency is increased by at least one additional bowel movement per week.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 10, 2018
From: HERCULES CAPITAL, INC.
To: JAGUAR HEALTH, INC.
Reel/Frame 045496/0039 →
SECURITY INTEREST Recorded Nov 22, 2017
From: NAPO PHARMACEUTICALS, INC.
To: KINGDON CAPITAL MANAGEMENT, L.L.C.
Reel/Frame 044497/0954 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2017
From: NANTUCKET INVESTMENTS LIMITED
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 043380/0655 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Feb 12, 2016
From: JAGUAR ANIMAL HEALTH, INC.
To: HERCULES TECHNOLGY GROWTH CAPITAL, INC., AS AGENT
Reel/Frame 037809/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2015
From: QUART, BARRY D.
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 035170/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2015
From: ROSENBAUM, DAVID P.
To: TRINE PHARMACEUTICALS, INC.
Reel/Frame 035170/0262 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2015
From: TRINE PHARMACEUTICALS, INC.
To: NAPO PHARMACEUTICALS, INC.
Reel/Frame 035170/0265 →
SECURITY AGREEMENT Recorded Mar 7, 2012
From: NAPO PHARMACEUTICALS, INC.
To: NANTUCKET INVESTMENTS LIMITED
Reel/Frame 027830/0255 →